# Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL

> **NCT05238064** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- PI3Kδ Inhibitor
- Parsaclisib
- CHOP
- PTCL

## Interventions

- **DRUG:** Parsaclisib
- **DRUG:** CHOP

## Key facts

- **NCT ID:** NCT05238064
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03
- **Primary completion:** 2025-03
- **Final completion:** 2025-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238064, "Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05238064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*